EA200600443A1 - TRANS-1- (6-HLOR-3-PHENYLINDAN-1-IL) -3,3-DIMETHILPIPERAZIN - Google Patents
TRANS-1- (6-HLOR-3-PHENYLINDAN-1-IL) -3,3-DIMETHILPIPERAZINInfo
- Publication number
- EA200600443A1 EA200600443A1 EA200600443A EA200600443A EA200600443A1 EA 200600443 A1 EA200600443 A1 EA 200600443A1 EA 200600443 A EA200600443 A EA 200600443A EA 200600443 A EA200600443 A EA 200600443A EA 200600443 A1 EA200600443 A1 EA 200600443A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- phenylindan
- dimethilpiperazin
- hlor
- trans
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
- C07C17/16—Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/18—Polycyclic aromatic halogenated hydrocarbons
- C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
- C07C35/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
- C07C35/32—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system being a (4.3.0) system, e.g. indenols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Предложены 4-((1R,3S))-6-хлор-3-фенилиндан-1-ил)-2,2-диметилпиперазин и его соли, фармацевтические композиции, содержащие указанное соединение и его соли, и его применение в медицине, включающее лечение шизофрении и других психотических расстройств.4 - ((1R, 3S)) - 6-chloro-3-phenylindan-1-yl) -2,2-dimethylpiperazine and its salts, pharmaceutical compositions containing this compound and its salts, and its use in medicine, including treatment of schizophrenia and other psychotic disorders.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301180 | 2003-08-18 | ||
DKPA200301305 | 2003-09-11 | ||
PCT/DK2004/000546 WO2005016901A1 (en) | 2003-08-18 | 2004-08-18 | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200600443A1 true EA200600443A1 (en) | 2006-08-25 |
Family
ID=58707237
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200600441A EA014641B1 (en) | 2003-08-18 | 2004-08-18 | Succinate and malonate salt of trans-4-((ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
EA200600443A EA200600443A1 (en) | 2003-08-18 | 2004-08-18 | TRANS-1- (6-HLOR-3-PHENYLINDAN-1-IL) -3,3-DIMETHILPIPERAZIN |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200600441A EA014641B1 (en) | 2003-08-18 | 2004-08-18 | Succinate and malonate salt of trans-4-((ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
Country Status (16)
Country | Link |
---|---|
KR (2) | KR101227789B1 (en) |
CN (1) | CN101935305B (en) |
AR (2) | AR045278A1 (en) |
AT (1) | ATE552247T1 (en) |
DK (1) | DK1658277T3 (en) |
EA (2) | EA014641B1 (en) |
ES (1) | ES2383369T3 (en) |
HK (2) | HK1096089A1 (en) |
IS (1) | IS8264A (en) |
ME (1) | MEP2408A (en) |
MY (2) | MY154535A (en) |
PT (1) | PT1658277E (en) |
RS (3) | RS20060083A (en) |
SG (2) | SG148183A1 (en) |
SI (1) | SI1658277T1 (en) |
TW (2) | TWI403505B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI453198B (en) * | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | Process for making the trans-1-( (1r , 3s)- 6-chloro - 3 -phenylindan-1- yl ) - 3 , 3 - dimethylpiperazine and salts thereof and for making 4 -((1r , 3s )-6- chloro- 3- phenylindan -1- yl )-1, 2 , 2 -trimethylpiperazine and salts thereof |
PL2720989T3 (en) | 2011-06-20 | 2017-05-31 | H. Lundbeck A/S | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE50867B1 (en) * | 1980-02-29 | 1986-08-06 | Kefalas As | Indane derivatives |
DK55192D0 (en) * | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindene derivatives |
-
2004
- 2004-08-18 MY MYPI20082882A patent/MY154535A/en unknown
- 2004-08-18 AT AT04762772T patent/ATE552247T1/en active
- 2004-08-18 TW TW099140932A patent/TWI403505B/en not_active IP Right Cessation
- 2004-08-18 KR KR1020067003177A patent/KR101227789B1/en active IP Right Grant
- 2004-08-18 SG SG200808521-9A patent/SG148183A1/en unknown
- 2004-08-18 DK DK04762772.4T patent/DK1658277T3/en active
- 2004-08-18 MY MYPI20043353A patent/MY149089A/en unknown
- 2004-08-18 RS YUP-2006/0083A patent/RS20060083A/en unknown
- 2004-08-18 SI SI200431885T patent/SI1658277T1/en unknown
- 2004-08-18 CN CN2010101632528A patent/CN101935305B/en not_active Expired - Fee Related
- 2004-08-18 SG SG200805893-5A patent/SG145723A1/en unknown
- 2004-08-18 PT PT04762772T patent/PT1658277E/en unknown
- 2004-08-18 RS YUP-2006/0121A patent/RS20060121A/en unknown
- 2004-08-18 AR ARP040102966A patent/AR045278A1/en not_active Application Discontinuation
- 2004-08-18 TW TW093124784A patent/TWI388550B/en not_active IP Right Cessation
- 2004-08-18 EA EA200600441A patent/EA014641B1/en not_active IP Right Cessation
- 2004-08-18 ES ES04762772T patent/ES2383369T3/en active Active
- 2004-08-18 AR ARP040102967A patent/AR045279A1/en not_active Application Discontinuation
- 2004-08-18 KR KR1020067003357A patent/KR20060066104A/en not_active Application Discontinuation
- 2004-08-18 ME MEP-24/08A patent/MEP2408A/en unknown
- 2004-08-18 EA EA200600443A patent/EA200600443A1/en unknown
- 2004-08-18 RS RS20060121A patent/RS53369B/en unknown
-
2006
- 2006-01-26 IS IS8264A patent/IS8264A/en unknown
-
2007
- 2007-03-21 HK HK07103032.7A patent/HK1096089A1/en not_active IP Right Cessation
-
2011
- 2011-06-29 HK HK11106689.0A patent/HK1152699A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EA014641B1 (en) | 2010-12-30 |
ATE552247T1 (en) | 2012-04-15 |
HK1096089A1 (en) | 2007-05-25 |
MY154535A (en) | 2015-06-30 |
AR045278A1 (en) | 2005-10-19 |
KR101227789B1 (en) | 2013-01-30 |
IS8264A (en) | 2006-01-26 |
SI1658277T1 (en) | 2012-10-30 |
CN101935305A (en) | 2011-01-05 |
KR20060066094A (en) | 2006-06-15 |
RS20060121A (en) | 2008-09-29 |
ES2383369T3 (en) | 2012-06-20 |
AR045279A1 (en) | 2005-10-19 |
RS20060083A (en) | 2008-08-07 |
MY149089A (en) | 2013-07-15 |
TWI403505B (en) | 2013-08-01 |
SG148183A1 (en) | 2008-12-31 |
TW201111351A (en) | 2011-04-01 |
HK1152699A1 (en) | 2012-03-09 |
TW200519098A (en) | 2005-06-16 |
DK1658277T3 (en) | 2012-06-18 |
KR20060066104A (en) | 2006-06-15 |
PT1658277E (en) | 2012-05-25 |
MEP2408A (en) | 2010-02-10 |
RS53369B (en) | 2014-10-31 |
CN101935305B (en) | 2013-04-10 |
SG145723A1 (en) | 2008-09-29 |
EA200600441A1 (en) | 2006-08-25 |
TWI388550B (en) | 2013-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061153L (en) | Trans-1- (6-chloro-3-phenylindan-1-yl) -3,3-dimethylpiperazine | |
AU2002344951A1 (en) | Substituted piperazine and diazepanes as histamine h3 receptor agonists | |
ATE454378T1 (en) | COMPOUNDS ACTIVE AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | |
EA200601239A1 (en) | REPLACED QUINOLINE COMPOUNDS | |
EA200401526A1 (en) | NEW CONNECTIONS AND THEIR APPLICATION | |
DE602004014361D1 (en) | USE OF OXAZOLIDINONE CHINOLIN HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | |
CY1111857T1 (en) | CRYSTAL BASE OF TRANS-1 - ((1R, 3S) -6-HULPO-3-FINYLINDAN-1-YLO) -3,3-DIMETHYLPIPERAZINE | |
SE0401970D0 (en) | Novel compounds | |
NO20074593L (en) | Tartrate and malate salts of trans-1- (6-chloro-3-phenylindan-1-yl) -3,3-dimethylpiperazine | |
ATE396970T1 (en) | 2-(1H-INDOLYLSULFANYL)-BENZYLAMINE DERIVATIVES AS SSRI | |
EA200701856A1 (en) | TETRAHYDROPYRIDAZAZEPIN-8-ONE AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | |
EA200701615A1 (en) | NEW MEDICINES FOR THE TREATMENT OF RESPIRATORY DISEASES | |
ATE422201T1 (en) | 4-(HETEROCYCLYL)-BENZENESULFOXIMINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
EA200600443A1 (en) | TRANS-1- (6-HLOR-3-PHENYLINDAN-1-IL) -3,3-DIMETHILPIPERAZIN | |
DE60316410D1 (en) | N-SUBSTITUTED 3-HYDROXY-4-PYRIDINONE AND PHARMACEUTICALS CONTAINING THEREOF | |
EA200701737A1 (en) | TRANS-1 - ((1R, 3S) -6-CHLOR-3-PHENILINDAN-1-IL) -3,3-DIMETYLPIPERAZINE | |
UA108342C2 (en) | METHOD OF PREPARATION OF 4 - ((1R, 3S) -6-CHLORO-3-PHENYLINDAN-1-IL) -1,2,2-TRIMETHYLPIPERASINE OR ITS SALT (OPTIONS), CIS- (1S, 3S) -6-CHLORINE 3-PHENYLINDAN-1-OL, CIS- (1S, 3S) -3-REPLACED-5-CHLORINE-1-PHENYLINDAN AND TRANS-1 - ((1R, 3S) -6-CHLORINE-3-PHENYLINDAN-1-IL ) -3,3-DIMETHYLPIPERASINE | |
SE0403118D0 (en) | New compounds 2 | |
SE0301442D0 (en) | Diarylmethylidene piperidine derivatives, preparations therof and uses thereof | |
CO5690574A2 (en) | NEW COMPOUNDS DERIVED FROM INDOLINA AS INHIBITORS OF CHOLESTEROL-ACTILTRANSPHERASE (ACAT) AND MEDICAL USE OF THE SAME |